Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-01-22

FDA Approved: SILIQ — Supplemental Application (Bausch Health US LLC)

View source ↗

Summary

FDA approved a supplemental Biologics License Application for SILIQ (brodalumab) submitted by Bausch Health US LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SILIQ (brodalumab)

Snippet

SUPPL AP for SILIQ (BRODALUMAB)